.
MergerLinks Header Logo

New Deal


Announced

Completed

Hyperfine and Liminal Sciences went public via a SPAC merger with HealthCor Catalio Acquisition in a c.$580m deal.

Financials

Edit Data
Transaction Value£420m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Synopsis

Edit

Hyperfine, a provider of technology solutions, and Liminal Sciences, a developer of medical devices, went public via a SPAC merger with HealthCor Catalio Acquisition, a blank check company, in a c.$580m deal. The transaction was supported by an oversubscribed $126m PIPE with participation from institutional investors including HealthCor Management, Catalio Capital Management, Perceptive Advisors, Avidity Partners, Eldridge, accounts managed by ARK Investment Management, Deerfield Management and Bain Capital. “The combination of Hyperfine, Liminal, and HealthCor Catalio presents an inspiring opportunity to transform the global MR imaging and brain sensing paradigm. This business combination will empower Hyperfine with the expanded resources, financing, and expert advisory team to substantially broaden MR imaging accessibility and ultimately build a transformational ecosystem across the care continuum,” Dave Scott, Hyperfine President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US